Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m 2 /day. Preclinical data in IC-treated tumor-bearing mice with low tumor burden documented striking antitumor effects. Patients with completely resectable recurrent stage III or stage IV melanoma were scheduled to receive 3 courses of IC at 6 mg/m 2 /day i.v. on days 1, 2 and 3 of each 28-day course. Patients were randomized to complete surgical resection either following neoadjuvant (Group A) or prior to adjuvant (Group B) IC course 1. Primary objectives were to: (1) evaluate histological evidence of anti-tumor activity and (2) evaluate recurrence-free survival (RFS) and OS. Twenty melanoma patients were randomized to Group A (11 patients) or B (9 patients). Two Group B patients did not receive IC due to persistent disease following surgery. Six of 18 IC-treated patients remained free of recurrence, with a median RFS of 5.7 months (95% confidence interval (CI) 1.8-not reached). The 24-month RFS rate was 38.9% (95% CI 17.5-60.0%). The median follow-up of surviving patients was 50.0 months (range: 31.8-70.4). The 24-month OS rate was 65.0% (95% CI 40.3-81.5%). Toxicities were similar to those previously reported. Exploratory tumor-infiltrating lymphocyte (TIL) analyses suggest prognostic value of TILs from Group A patients. Prolonged tumor-free survival was seen in some melanoma patients at high risk for recurrence who were treated with IC.
Introduction
Immunotherapeutic strategies for melanoma have evolved over the past 25 years from systemic activation of the immune system via administration of high-dose IL-2 to molecularly targeted vaccines, adoptive immunotherapy, antitumor monoclonal antibodies and several antibodies that help activate the immune system via "checkpoint blockade" [3] [4] [5] [6] . One of the potential benefits of immunotherapy is the ability to destroy not only grossly visible disease but also micrometastases, which have been a significant barrier to achieving long-term benefit from locally driven modalities such as surgery and radiation, as well as a challenge for cytotoxic chemotherapy. Often these sites of micrometastatic disease are able to withstand initial therapeutic efforts only to recur at a later date with significant morbidity and mortality. An ideal therapy would be one that is well-tolerated, tumor-specific, and able to manage both macro-and microscopic sites of disease.
The hu14.18-IL2 IC is a humanized mAb that is covalently linked to two molecules of IL-2 at the Fc region [7, 8] . The hu14.18 mAb recognizes GD2, a disialoganglioside that is a cell membrane molecule found in tumors of neuroectodermal origin (including melanoma, neuroblastoma, and certain sarcomas) while relatively rare in normal tissues (mostly cerebellum and peripheral nerves) [9] [10] [11] . This IC has been studied extensively in vitro and in preclinical models, including both melanoma and neuroblastoma [12] [13] [14] [15] [16] , and has undergone both Phase I and II testing in adults with melanoma and children with neuroblastoma [17] [18] [19] [20] . In mice, the antitumor effect of hu14.18-IL2 against melanoma and neuroblastoma can involve T cells and NK cells [12, 16, 21] . Mice with smaller tumors or with minimal residual disease show the best responses to IC [16] . Hu14.18-IL2 given i.v. to adults with melanoma or children with neuroblastoma was generally well-tolerated and was able to produce demonstrable immune activation ex vivo and in vivo [18] [19] [20] . However, i.v. hu14.18-IL2 had minimal antitumor effects for patients with measurable disease in Phase II trials: 0 responses of 15 patients with neuroblastoma; and 1 transient partial response (PR) and 0 complete response (CR) of 14 patients with melanoma in our Phase II trials [17, 20] . In contrast, and consistent with our preclinical data, patients with evaluable but non-bulky, non-measurable disease (neuroblastoma patients with disease evaluable only by 123 MIBG scintigraphy or by bone marrow histology) showed reproducible antitumor activity: 5 of 24 evaluable patients with CR [20] . We now evaluate hu14.18-IL2 in advanced melanoma patients who achieved a complete response through surgery.
Materials and methods

Patients
Twenty patients with advanced melanoma participated in this trial [University of Wisconsin (UW) Carbone Cancer Center Protocol CO05601]. Initially this protocol was designed to evaluate the effect of hu14.18-IL2 and of cilengitide, alone and in combination, for patients with stage III or stage IV melanoma thought to have completely resectable disease. The protocol opened in the spring of 2008, with patients randomized to one of four groups. Based on toxicities seen in one patient who received both cilengitide alone (course 1) and hu14.18-IL2 in combination with cilengitide (course 2), enrollment was suspended after the initial 4 patients, including 3 patients treated with cilengitide. The protocol was then amended to drop the treatment groups with cilengitide and proceed with enrollment and randomization using the treatment groups containing only hu14.18-IL2. The 3 patients who also received cilengitide are excluded from the study analyses (toxicity, outcome and lab data) in this report.
All 20 patients had recurrent stage III (i.e., recurrent regional metastasis), or stage IV (i.e., any distant metastasis) melanoma for which surgical resection would be clinically recommended, with biopsy proven (current or previous) stage III or stage IV disease (staging was according to the 7th edition of the American Joint Committee on Cancer [AJCC] Cancer Staging Manual). Patients needed to have disease that had not yet been completely excised and involved three or fewer sites. "Clustered" nodal, subcutaneous, or cutaneous lesions that could be removed in a single surgical excision were scored as one site. Patients could have: (1) stage III melanoma with recurrence after prior surgery, with or without subsequent adjuvant therapy, or (2) stage IV melanoma (cutaneous, ocular, mucosal, or unknown primary) without any prior systemic therapy for stage IV disease. Patients needed to have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1 and adequate end organ function. Patients with active or inactive brain metastases were ineligible.
Hu14.18-IL2
The hu14.18-IL2 (APN301) IC was supplied collaboratively by the National Cancer Institute-Biological Resources Branch (NCI-BRB, Frederick, MD) via a cooperative research and development agreement, currently held by Apeiron Biologics (Vienna, Austria). Preclinical evaluation has shown that 1 mg of hu14.18-IL2 contains approximately 3 × 10 6 units of IL-2 (based on a proliferative assay with IL-2 responsive Tf-1 beta cells) and approximately 0.8 mg of the hu14.18 mAb [13] .
Study design
Eligible patients were enrolled and randomized into two Groups. The design was for patients in Group A to receive surgical resection after the 1st course of neoadjuvant hu14.18-IL2 and then to receive two subsequent courses of adjuvant hu14.18-IL2 following their surgical resection. Patients in Group B were to receive their surgical resection prior to the 1st of 3 courses of adjuvant hu14.18-IL2. Patients were randomized to Group A or B in a 1:1 ratio using permuted blocks of size 4, stratified by type of surgical resection (extensive vs. non-extensive). The treatment schema for each study Group is shown in Supplementary  Fig. S1 . Patients were scheduled to receive hu14.18-IL2 on days 1, 2, and 3 of each course of therapy as a 4-h continuous i.v. infusion at a daily dose of 6 mg/m 2 /day. Patients were scheduled to receive a total of three 28-day courses of treatment at the same dose level provided that there was no dose limiting toxicity (DLT) or significant non-DLT toxicity. The protocol allowed for two dose modifications for DLT or significant non-DLT toxicity: the first a 50% dose reduction to 3 mg/m 2 /day, and the second an additional 50% dose reduction to 1.5 mg/m 2 /day. Missed doses were not made up, and all dose reductions were permanent.
Surgical considerations
All patients were assessed by a surgical oncologist and needed to have completely resectable disease in three or fewer sites. In the event that the pathologic margins demonstrated microscopic residual disease, patients could remain on protocol provided that the disease evaluation following course 2 demonstrated no radiographically or clinically evident disease. Patients with stage IV disease could have visceral disease, cutaneous disease, and/or subcutaneous disease. Surgical resection was considered "extensive" if it required thoracotomy, laparotomy or excision of deep soft tissue metastases in three anatomic locations. Surgical resection was considered "non-extensive" if it involved only cutaneous/subcutaneous excisions and/or excision of deep soft tissue disease in only one or two locations.
Toxicity grading and dose modifications
DLT was defined as Grade 3 or 4 toxicity, using the NCI Common Terminology Criteria Adverse Events (CTCAE), version 3.0, except for selected, previously reported toxicities representing known side effects of IL-2 and hu14.18-IL2 therapy that are generally transient and well-controlled clinically [17, 18] . Those previously reported toxicities, if seen, were graded and recorded but not used as criteria for determining DLTs as they were expected, based on observations of hu14.18-IL2 given to 33 adults with melanoma, administered by the same schedule at similar doses to that being tested in this trial [18] . All Grade 4 toxicities (except for transient lymphopenia) were considered DLT and required stopping treatment with hu14.18-IL2. For any occurrence of DLT, treatment with protocol therapy was stopped. Treatment could not be resumed with dose modification until after the toxicity resolved to meet original eligibility criteria.
Immunologic monitoring
Peripheral blood samples were obtained from all patients to measure C-reactive protein (CRP) levels and to determine lymphocyte counts. The CRP assay and lymphocyte counts were performed by the UW Hospitals and Clinics (UWHC) clinical lab. Serum ELISA assays determined the peak hu14.18-IL2 serum levels achieved with each i.v. infusion during the 3 courses of hu14.18-IL2, as previously described [1, 18] . Serum obtained following therapy was also assayed for the generation of an antibody response to the hu14.18-IL2 immunocytokine, as previously described [19] . Serum soluble IL-2 receptor (sIL-2R) alpha levels were determined using the Human CD25/IL-2 R alpha DuoSet ELISA Kit (R&D Systems, Minneapolis, MN, catalog number DY223), following manufacturer's instructions.
Processing and histological analyses of tumor biopsies
Each patient's surgical resection specimen (obtained following neoadjuvant IC course 1 for Group A and before adjuvant IC course 1 for Group B) was processed by UWHC Surgical Pathology. Representative sections of each patient's tumor were coded and given blindly to our board-certified anatomic pathologist (author Dr. Erik A. Ranheim) for diagnosis confirmation and TIL assessment on H&E slides. Quantitation of TILs percentage was performed using the following equation: quantitation of TILs percentage (%) = (cross-sectional area of TILs/area of tumor) × 100. TILs were tightly defined as truly "infiltrating" by applying the following parameters: (1) lymphocytes need to be imbedded between tumor cells, (2) exclude lymphocytes at the tumor invasive margin, (3) exclude lymphocytes touching vasculature, (4) exclude lymphocytes touching other lymphocytes, (5) exclude plasma cells, macrophages, or granulocytes. Immunohistochemical staining for CD3, CD4, CD8, CD20, CD56, and CD68 was performed using a Ventana system (Roche, Tucson, Arizona) on paraffinembedded sections to confirm the identity of the TILs. Assessment of GD2 expression was performed on frozen sections of the tumor biopsies using the mouse anti-GD2 mAb clone 14.G2a (Santa Cruz Biotechnology, Dallas, TX). Following overnight incubation in 1% rabbit serum and washing, a biotinylated rabbit anti-mouse secondary Ab was applied for 90 min, followed by an avidin-biotin complex (ABC, Vector Laboratories, Burlingame, CA). Slides were developed with 3,3-diaminobenzidine (DAB, Vector Laboratories) for 4.5 min, counterstained with Mayer's hematoxylin (Sigma, St. Louis, MO) for 90 s, washed in running tap water for 5 min, and mounted.
Statistical analysis
The primary objectives were: (1) evaluate the histological evidence of antitumor activity (apoptosis/necrosis) of hu14.18-IL2 in subjects with advanced melanoma who have achieved a CR through surgical resection of all known metastatic disease approximately 1 week following the first course of neoadjuvant treatment with hu14.18-IL2, and (2) evaluate RFS and OS following treatment with neoadjuvant and/or adjuvant hu14.18-IL2 in subjects with biopsy-proven recurrent stage III or stage IV melanoma who have achieved a CR through surgical resection of all known metastatic disease. RFS was defined as the number of days from the day of evaluation following course 2 of IC treatment to the day the subject experienced an event of recurrence or death, whichever occurred first. Patients who did not experience an event of recurrence or death at the time of analysis were censored at the date of the last evaluation for recurrence. OS was defined as the number of days from randomization to the date of the patient's death. Patients who did not experience an event of death at the time of analysis were censored at the date of the last follow-up. RFS and OS were analyzed using the Kaplan-Meier (KM) methodology for both Groups combined. RFS and OS were compared between the GD2 Groups using log-rank tests. Continuous variables were summarized using median and ranges, and categorical variables were summarized using frequencies and percentages. The change in CRP and lymphocyte counts from baseline were secondary endpoints that were evaluated using a Wilcoxon signed rank test for within Group comparisons and a Wilcoxon rank sum test for between Group comparisons. The TIL data analysis and graphs were generated and significance tests were performed using Prism 7, version 7.02, software (GraphPad). Due to the exploratory nature of the statistical inference for the TIL data, no adjustments were made for multiple testing. The immune activation graphs were generated using R, version 3.5.0, and the ggplot2 package, version 2.2.1 [22] .
Results
Patient characteristics
A total of 20 eligible patients were enrolled between March 28, 2008 and May 4, 2012. Of these 20 patients, 11 were randomized to Group A and nine to Group B. Two patients in Group B were not treated with adjuvant hu14.18-IL2: one patient was taken off protocol after surgery due to extensive disease identified at that time, and the second patient was taken off protocol after surgery due to findings noted on the PET/CT scan prior to the first adjuvant IC course. Subsequently these two patients were excluded from the RFS analysis but included in the OS analysis.
The baseline characteristics of the 20 patients randomized to Group A or B are provided in Table 1 . Thirteen of the 20 patients were men, the median age was 46 years (range, 21-69 years), and all patients were ECOG performance status of 0 or 1. Fourteen of the patients received prior systemic adjuvant therapy.
Treatment summary
The treatment summary of patients is shown in Table 2 . Six of the 20 patients had an "extensive surgical resection", and 14 of the 20 patients had a non-extensive surgical resection. Two of the patients (sequence numbers 12 and 15) did not proceed to receive hu14.18-IL2 as each patient had disease that could not be completely resected with surgery. Ten of the 18 IC-treated patients received all planned hu14.18-IL2 infusions without treatment modifications. Hu14.18-IL2-associated toxicities that required treatment modifications included: hypotension (three patients); syncopal episode (one patient); elevated AST (two patients); elevated bilirubin (one patient); elevated creatinine with decreased urine output (one patient); and pain (one patient). One of the three patients (sequence number 10) who experienced hypotension at 6 mg/m 2 also experienced recurrent hypotension during subsequent courses requiring dose modification at 3 mg/m 2 and at 1.5 mg/m 2 . One of the three patients (sequence number 18) who had a dose modification due to hypotension experienced that toxicity at an hu14.18-IL2 dose which had been reduced to 3 mg/m 2 due to pain after course 1. The anticipated IL-2 constitutional symptoms (fever, chills, fatigue, pruritus, and myalgias) were seen in the majority of patients treated with hu14.18-IL2. Many patients also had transient Grade 1 and 2 laboratory changes that were similar to those reported in our prior phase I and phase II studies of hu14.18-IL2 [17, 18] . Only Grade 3 and 4 adverse events (AEs) as well as AEs requiring dose modification were collected in this study, and a summary of the collected clinical and laboratory AEs is provided as supplementary data (Supplementary Table S1 ). Overall, the AEs seen in this study were similar to previously described AEs with hu14.18-IL2 [17, 18] . Intravenous fluids were used for transient hypotension for five patients (occurrences in ten courses). Eight patients (occurrences during 12 doses) received intravenous opioids for management of pain associated with infusion of hu14.18-IL2. The hu14.18-IL2 associated toxicities experienced by patients in this study were reversible.
Immunologic monitoring
In vitro studies were performed to monitor various aspects of the immune response to hu14.18-IL2. As previously reported, lymphopenia was seen on day 3 of each course and followed by lymphocytosis (data not shown) [17, 18] . The change in lymphocyte count rose from baseline to course 2, day 1 for Groups A and B (p < 0.001 and p = 0.016, respectively), as noted previously. We also monitored values of CRP over time as a measure of immune activation (data not shown). There was a significant difference in the change in CRP values from baseline to course 1, day 3 for Group A (p = 0.002) and Group B (p = 0.016). Serum ELISA assays showed that the trends in peak IC levels were consistent across the three courses of therapy with low baseline levels followed by sharply increased levels 4 h post-IC infusion (Fig. 1a) . Dose reduction modifications were required during the study for patients in both groups (Table 2) . IC dose was reduced 50% for three patients in Group A beginning at course 2, day 1, and for one of these three patients, the IC dose was further reduced 75% in course 3. IC dose was reduced 50% for two patients in Group B beginning at course 2, day 1, and for a third patient in Group B the IC dose was reduced 50% for the last dose of course 3 (course 3, day 3). Peak IC levels detected were generally lower following dose modifications as compared to course 1 levels on an individual patient level (i.e., before dose reduction) (data not shown). All 18 IC-treated patients developed antibodies to the hu14.18-IL2 immunocytokine that could be measured in a bridging ELISA assay at some point during the course of treatment (Supplementary Fig. S2 ). In 17 of the 18 IC-treated patients, the highest level of bridging activity was not at the end of therapy (i.e., course 3, day 3) and the level of anti-IC antibody did not interfere with the detection of the IC with subsequent infusions. The exception was a Group A patient (sequence number 20) where there was a substantial level of bridging activity at the end of course 2 which was maintained during course 3 and significantly limited the detection of the IC in the serum during course 3. Bridging activity is measured in OD units and serial dilution of patient 20's serum resulted in corresponding reductions of the OD such that at a dilution of 1/125, the anti-IC level was at background levels (data not shown).
The level of sIL-2R alpha is an indication of immune activation and Fig. 1b indicates a significant increase in the (100) 19 (95) sIL-2R alpha during the 3 courses of therapy. This increase was seen in patient 20 even in the presence of anti-IC antibodies which limited the detection of the IC in the serum. The increases in sIL-2R alpha levels detected over the course of this study recapitulated the levels of CRP detected (data not shown).
Histology of tumor biopsies
A wide range of histologic patterns of lymphoid inflammation were evident, even prior to treatment ( Supplementary  Fig. S3 ). Twelve patients had evaluable tumor samples for GD2 analysis. Frozen sections of patient tumor biopsies were stained by IHC to evaluate GD2 expression. Tumors fell into three categories, near complete GD2 staining of tumor cells in a membrane and granular cytoplasmic pattern, partial GD2 staining in 10-40% of tumor cells, or predominantly absent GD2 staining ( Supplementary Fig. S4 ). The GD2 results were summarized in terms of positive (GD2 expression high or low/moderate; n = 6) and negative (GD2 expression undetectable; n = 6) for analysis of RFS and OS (see following section).
Efficacy
The KM estimate of the survival distribution for RFS is shown in Fig. 2 ; the median RFS was 5.73 months [95% CI 1.80-not reached (months)]. There was no difference in RFS by GD2 status (Supplementary Fig. S5 ). The KM estimate of the survival distribution for OS is given in Fig. 3 ; the median OS was 61.57 months [95% CI 13.67-not reached (months)]. There was no difference in OS by GD2 status (Supplementary Fig. S6 ).
Tumor-infiltrating lymphocyte analyses
Quantitation of TIL from resected tumors from the 18 ICtreated patients revealed a median TIL percentage of 5% (of all cells). This was used as the cut-off to categorize low vs. high TIL (Fig. 4a, b) . Of the patients who received neoadjuvant hu14.18-IL2 prior to surgical resection (n = 11) (Group A), those whose tumors had high TILs post-IC neoadjuvant therapy (> 5%, n = 6) had increased RFS (median = 43.2 months) compared to patients whose tumors had low TILs post-IC neoadjuvant therapy (0-5%, n = 5, median = 2.33 months, p = 0.0121) (Fig. 4c) . Also, Group A patients whose tumors had high TILs (> 5%, n = 6) had a non-significant trend toward increased OS (median not yet reached) compared to patients whose tumors had low TILs (0-5%, n = 5, median = 22.2 months, p = 0.0842) (Fig. 4d) . These comparisons were not significant in patients who received adjuvant hu14.18-IL2 after surgical resection (Group B); there was no significant difference in RFS or OS for the Group B patients with high TILs vs. low TILs (Fig. 4c, d ).
Discussion
Our data show that surgery combined with administration of 3 courses of the hu14.18-IL2 immunocytokine at an i.v. dose of 6 mg/m 2 /day on days 1, 2 and 3 of each 28-day course can result in prolonged tumor-free survival in some melanoma patients at high risk for recurrence and death. There was no difference in RFS or OS by GD2 status in the 12 patients with evaluable tumor samples for GD2 analysis. The RFS and OS endpoints, along with histological analysis of resected melanoma for anti-tumor activity mediated by hu14.18-IL2, were primary endpoints of this study. The current data are mature, as the median follow-up of surviving patients is over 4 years (range: 31.8-70.4 months).
The patients in this study had a very high risk of relapse, as eligibility required patients to have recurrent stage III (i.e., recurrent regional metastasis), or stage IV (i.e., any distant metastasis) melanoma for which surgical resection would be clinically recommended. All 20 patients had biopsy confirmation (current or previous) of stage III or stage IV disease. Fourteen of the 20 patients had prior systemic adjuvant therapy, and 7 of the 20 patients had stage IV disease.
There have been major recent advances in systemic adjuvant therapy for patients with resected high-risk melanoma [23] [24] [25] . These advances include checkpoint inhibitor immunotherapies, including drugs that target PD-1 or CTLA-4, and drugs that target the MAPK pathway (BRAF and MEK inhibitor combination). Findings from these recently reported studies provide a perspective to interpret our data. The use of adjuvant ipilimumab resulted in a significantly higher rate of 5-year survival than placebo (65.4 vs. 54.4%) for patients with resected stage III melanoma [23] . The use of adjuvant nivolumab resulted in a significantly higher 12-month RFS rate than ipilimumab (70.5 vs 60.8%) for patients with resected stage IIIB, IIIC, or IV melanoma [25] . Previous systemic therapy for melanoma was not allowed. The use of adjuvant dabrafenib plus trametinib resulted in a significantly higher 3-year RFS rate than placebo (58 vs 39%) for patients with resected stage III melanoma [24] . Previous systemic therapy for melanoma was not allowed.
The higher baseline recurrence risk and the smaller sample size of our study does not allow direct comparison of RFS and OS rates with patient subsets from the recent large prospective adjuvant melanoma studies [23] [24] [25] . However, the 24-month RFS rate was 38.9% (95% CI 17.5-60.0%) and the 24-month OS rate was 65.0% (95% CI 40.3-81.5%) for the 20 high-risk patients in our study. A prospective randomized study would be needed to determine whether surgery combined with administration of 3 courses of the hu14.18-IL2 immunocytokine given intravenously, alone or in combination with immune checkpoint blockade, improves RFS or OS compared to any of the currently approved adjuvant therapies. A trial design of neoadjuvant hu14.18-IL2 to induce a lymphocytic infiltration into tumors, followed by adjuvant anti-PD1 therapy after surgery, is suggested for subsequent investigation.
The hu14.18-IL2 dose for this trial was 6 mg/m 2 and was one dose level below the maximum tolerated dose of 7.5 mg/ 2 established in our phase I trial [18] . This dose and schedule (6 mg/m 2 /day for three consecutive days) was previously shown to result in immune activation and to be well tolerated with reversible toxicities in our prior phase II study of 14 patients with measurable metastatic melanoma [17] . In previous studies, we have shown that some patients develop antibodies to the hu14.18-IL2 immunocytokine that can be measured in a bridging ELISA assay [26] . We found that all 18 IC-treated patients developed a bridging antibody at some point during the course of treatment ( Supplementary Fig.  S2 ), but this anti-IC antibody did not appear to affect serum levels of IC in 17 of those 18 patients. Importantly, immune activation was achieved in the patients in this study as evidenced by rebound lymphocytosis, elevated CRP, and sIL-2R alpha. The spectrum of toxicities experienced by patients in this study were similar to those previously reported for melanoma patients receiving this same IC dose and schedule and were readily managed and were reversible [17] .
The current study was designed to allow for histological analysis of resected melanoma for anti-tumor activity mediated by hu14.18-IL2, as patients in Group A received their surgical resection after the first course of neoadjuvant hu14.18-IL2 and patients in Group B received their surgical resection prior to the first course of adjuvant hu14.18-IL2. We only collected and evaluated the tumors obtained at surgical resection, additional biopsies of different sites or at different times were not obtained. While the histological analysis identified inflammation and tumor necrosis in many tumor samples, the variability in immune infiltrate between anatomic sites was substantial and did not allow for an instructive comparison of inflammation and tumor necrosis between Groups. In the future, we plan to prospectively collect biopsies before and after hu14.18-IL2 from the same tumor sites in each patient.
We proceeded with exploratory analyses of TIL to evaluate whether quantification of TIL would provide a biomarker of response for patients treated with IC. Quantification of TIL in the resected tumors did not provide prognostic information for patients who underwent surgical resection prior to receiving adjuvant hu14.18-IL2 (Group B). In contrast, patients who received neoadjuvant hu14.18-IL2 prior to surgical resection (Group A) and had tumors with high TILs had increased RFS compared to Group A patients whose tumors had low TILs (Fig. 4c) . In addition, patients whose tumors had high TILs (6-100%, n = 6) following treatment with neoadjuvant hu14.18-IL2 had a trend towards increased OS compared to patients whose tumors had low TILs following hu14.18-IL2. We interpret this to suggest that patients who are unable to mount a TIL infiltrate following neoadjuvant IC therapy appear to be less likely to respond clinically and vice versa. With the caveat of low sample size, the degree of TIL infiltration present prior to adjuvant IC therapy (i.e., in Group B patients) did not appear to be predictive of IC responsiveness. In our preclinical testing in mice bearing the syngeneic B78 melanoma, we have seen that the combination of low dose radiation therapy followed by intratumoral administration of IC causes a potent infiltration of T cells into tumors and dramatically potentiates the response of relatively large murine melanomas to anti-CTLA-4 treatment [21] . Planning for clinical testing of this combination is being initiated.
In conclusion, patients with resectable recurrent stage III or stage IV melanoma can experience prolonged tumor-free survival following surgery and 3 courses of IC. We suggest prospective testing of early post-treatment TIL as a biomarker of response for immunotherapy that includes IL2. Additional investigations are needed to determine whether hu14.18-IL2, either alone or as a combination therapy, can improve upon current adjuvant treatment options for patients with resected high-risk melanoma.
